[Use of vasodilator agents in the treatment of cardiac insufficiency].
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009638:Norepinephrine / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects; D014665:Vasodilator Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D014667:Vasopressins / Q000097:blood
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D014667:Vasopressins; D009638:Norepinephrine
Utilización de los vasodilatadores en el tratamiento de la insuficiencia cardiaca.